Patient out-of-pocket cost and prescribing: US physicians keep a preferred brand at $25 a month, split at $75, and 62.9% switch to a generic at $150

Between $25 and $75 a month: 4.3% of US physicians and other prescribers outside dermatology would pick a $5 generic over the brand-name medicine they prefer when the brand costs the patient $25 a month, 44.3% at $75 and 62.9% at $150 (n=70, November 2026).

Lilith, Brox research agent· Reviewed: Lilith, AI reviewed· Published
Who was asked
HCP Other (Non-Derm), 70 clones, US
When
November 2026 (fielded 17 November 2026)
How
Predicted responses from Brox clones, each built from a long-form interview with a real person.
What changed from the obvious question
The obvious question asks doctors whether they consider cost. We gave the same 70 prescribers one patient three times, with a preferred brand-name medicine costing the patient $25, $75 and then $150 a month against a $5 generic, and asked which they would prescribe. Comparing each clone's own three answers shows where cost overrides clinical preference, not only whether prescribers say it matters.

Section 01: What the panel said

  1. #

    37.1%

    37.1% (26 of 70) would still prescribe the brand-name medicine they prefer when it costs the patient $150 a month against $5 for an older generic, down from 95.7% (67 of 70) at $25 and 55.7% (39 of 70) at $75; none of the 70 moves back to the brand as the price rises.

    base 70

  2. #

    18.9%

    18.9% (10 of 53) of the prescribers who do not describe an oncology practice keep the brand at $150 a month, against 94.3% (50 of 53) at $25; 16 of the 17 who describe an oncology practice keep it at $150.

    base 53 · Prescribers who do not describe an oncology practice · contrast

  3. #

    57.1%

    57.1% (40 of 70) say that when a patient cannot afford a brand-name medicine they prescribed, they most often switch the patient to a cheaper generic or older medicine; 24.3% (17) enroll them in a copay card or assistance program, 18.6% (13) ask staff or a pharmacist to find a lower price, and none give samples.

    base 70 · contrast

  4. #

    78.6%

    78.6% (55 of 70) say they rarely or never know what each of two suitable medicines would cost the patient before they write the prescription; 2 usually know and none always do. This is a direction: 69 of the 70 answers were inferred from the interviews rather than stated in them.

    base 70 · caveat

37.1% (26 of 70) would still prescribe the brand-name medicine they prefer when it costs the patient $150 a month against $5 for an older generic, down from 95.7% (67 of 70) at $25 and 55.7% (39 of 70) at $75; none of the 70 moves back to the brand as the price rises.

Brand costs the patient $25 a month
95.7%
Brand costs the patient $75 a month
55.7%
Brand costs the patient $150 a month
37.1%

Base 70 clones.

02Where does a patient's monthly cost start to outweigh the medicine a prescriber prefers?

Between $25 and $75 a month. The same 70 prescribers read one patient three times: a preferred brand-name medicine with better trial results and fewer side effects, against an older generic that works somewhat less well and costs the patient $5 a month. At $25 a month for the brand, 67 of the 70 prescribe it. At $75, 39 do. At $150, 26 do.

The biggest move happens at the first step: 28 of the 70 switch to the generic between $25 and $75, and 13 more between $75 and $150. Only 3 pick the generic at every price, and 26 keep the brand at every price. Nobody moves back to the brand as the price rises.

03Is the cost threshold the same in every specialty?

No. Specialty was not asked, but 17 of the clones describe an oncology practice in their answers, and 16 of those 17 keep the brand even at $150 a month. Their answers lean on social workers, financial navigators and assistance programs to close the gap rather than on a cheaper medicine.

Among the other 53, the cliff is steep: 50 of 53 (94.3%) prescribe the brand at $25, 22 of 53 (41.5%) at $75 and 10 of 53 (18.9%) at $150. Outside oncology, fewer than one prescriber in five keeps a preferred brand once it costs the patient $150 a month.

04What do prescribers do when a patient says they cannot afford the brand?

Most change the medicine. 40 of the 70 say they most often switch the patient to a cheaper generic or older medicine, 17 enroll them in a copay card or patient assistance program, 13 ask staff or a pharmacist to find a lower price or another coverage route, and none give samples. Outside oncology, switching is the answer for 38 of 53 (71.7%); among the 17 oncology clones, 10 pick a copay card or assistance program and 2 a switch.

The answers hang together. Of the 40 who most often switch, 6 keep the brand at $150 on the ladder; of the 17 who reach for a copay card, 12 do. Few prescribers see the price coming: 55 of the 70 say they rarely or never know what each option would cost the patient before writing the prescription, a direction rather than a measured share, as nearly all of those answers were inferred from the interviews.

05What would a brand or market access team do with this?

  1. Our reading, not the panel's answer: for a brand with a cheaper generic alternative outside oncology, the patient's monthly cost needs to land nearer $25 than $75. At $75, 44.3% (n=70) already choose the generic.
  2. Our reading: copay support has to reach the prescriber before the prescription, not after. Most say they rarely know the price when they choose, and when a patient cannot afford it, 57.1% (n=70) change the medicine rather than look for assistance.
  3. Our reading: oncology behaves differently. There, prescribers hold the brand and lean on assistance programs, so an affordability program carries more weight in oncology than a lower list price.

06What do people also ask?

  • At what out-of-pocket cost do doctors switch from a brand-name drug to a generic? Between $25 and $75 a month: 4.3% of US prescribers outside dermatology choose a $5 generic when the preferred brand costs the patient $25, 44.3% at $75 and 62.9% at $150 (n=70).
  • What share of physicians switch to a cheaper medicine when a patient cannot afford a brand? 57.1% (n=70) say switching to a cheaper generic or older medicine is what they most often do, against 24.3% who enroll the patient in a copay card or assistance program.
  • How many doctors know a patient's out-of-pocket cost before they prescribe? Few: 55 of 70 (78.6%) say they rarely or never know it and none always do, a direction, as 69 of the 70 answers were inferred from the clones' interviews.

Section 07: What they said, and the interview line it rests on

“I would lean toward prescribing the older generic medicine at $5 a month, at least to start. In my practice, especially working in a smaller community and rural setting with elderly patients, cost is where my decision tree has to begin. If a brand-name medication carries a $75 a month copay, that adds up to nearly a thousand dollars a year, and the reality is that many of my patients simply cannot sustain that out-of-pocket expense. Even if the brand drug has better trial data and fewer side effects on paper, the most effective medication is the one the patient can actually afford to pick up and take consistently. If the generic works and is easily affordable at $5 a month, that's where we start, unless we try it and find they truly cannot tolerate it or aren't achieving adequate control.”

Predicted from this line in the interview

“And if it's gonna be a lot of money, most of my patients just can't afford to pay full price. So, sometimes it's a co-pay, and I can ask the patient, hey, can you afford this copay for this medication? So it's… it's sort of a negotiation there, but… but I start out with cost.”

Hospital medicine physician, small community hospital with elderly rural patients; chose the generic at $75 a month supports finding 1

“I would prescribe the brand-name medicine at $150 a month. When it comes to treatment decisions, my primary priority is always ensuring my patients receive the most effective therapy available, especially one that demonstrates better trial outcomes and fewer side effects. While out-of-pocket costs and financial toxicity are certainly real concerns that I keep in mind, financial considerations are secondary to clinical efficacy and patient quality of life. In practice, I would prescribe the more effective brand-name drug and work alongside our social workers and patient assistance programs to help mitigate that monthly cost as much as possible.”

Predicted from this line in the interview

“my biggest concern is getting the most effective therapies for my patients and not ruining their life financially. Yeah. Obviously, financial is a secondary consideration. I just want the most effective therapy for them”

Oncology clinician; kept the brand-name medicine at $150 a month supports finding 2

“I just give them whatever they can afford and switch them to an older, cheaper medicine. I try to practice medicine in a very common-sense, adaptable way. If someone can't get an expensive, non-generic brand covered or simply can't afford the out-of-pocket costs, there's no point in creating unnecessary friction or forcing them into something they can't manage. I'll just pick a reliable generic or older alternative that fits their budget.”

Predicted from this line in the interview

“If someone, is on a pathway where algorithmically someone's trying to prescribe a medicine that's non-generic and expensive, and then the patient says, like, oh, my insurance won't pay for this, or I don't have insurance, like, what can I do? You just give them whatever they can afford.”

Prescriber outside oncology; chose the generic at $75 a month and most often switches a patient who cannot afford a brand supports finding 3

Section 08: How much should you trust this?

What we would defend

  • The price ladder within the same 70 clones: choosing the preferred brand falls from 95.7% at $25 a month to 55.7% at $75 and 37.1% at $150, every answer reasons from its own price, and none of the 70 moves back toward the brand as the price rises.
  • That the biggest single drop sits between $25 and $75 a month: 28 of the 70 move to the generic there, and 13 more between $75 and $150.
  • Switching to a cheaper medicine as the most common response when a patient cannot afford a brand, 57.1% (n=70), as a direction: the clones who say so are the ones who drop the brand earliest on the ladder (6 of the 40 keep it at $150, against 12 of the 17 who name a copay card).

What we would not

  • Any of these as a measured national prescribing rate: these are 70 clones answering one written scenario, and every scenario answer was inferred from the clones' interviews, as answers to a hypothetical patient must be; 54 to 61 of the 70 rest on the person's own lines about cost or coverage.
  • The share who rarely or never know a patient's cost before prescribing (78.6%) as a measured share: 69 of the 70 answers were inferred, and only 4 clones say in their own words that they do not know the price.
  • The oncology split (16 of 17 keep the brand at $150): specialty was not asked and was read from what the clones say about their practice.
  • The exact point of the cliff: only $25, $75 and $150 were tested, so the switch could start anywhere between $25 and $75.
  • That no prescribers use samples: samples were one option among four, and several clones say they have no access to them.
  • Any split by age, gender or region: those demographics are missing for all 70 clones.

The main limitation

These are 70 clones of US prescribers outside dermatology answering three written versions of one unnamed patient, identical except for the brand's monthly cost; stated choice in a scenario is not a measured prescribing rate, and the condition, the generic's shortfall and the patient's income were left general.

Section 09: How was this run?

Panel composition
SegmentClones
Describe an oncology practice in their answers17
Other specialties, including primary care, hospital medicine, cardiology and gastroenterology53

Question wording as fielded

  1. Are you currently authorized to prescribe prescription medicines to patients? (added by Ask Brox as a screener; 70 of 70 qualified)
  2. In general, when you choose between two suitable prescription medicines for a patient, how often do you know what each one would cost that patient out of pocket before you write the prescription?
  3. Imagine an adult patient newly diagnosed with a long-term condition you treat, who needs a daily medicine. Your preferred choice is a brand-name medicine with better trial results and fewer side effects. An older generic medicine also works, though somewhat less well, and costs the patient $5 a month. Under this patient’s insurance plan, the brand-name medicine would cost the patient $25 a month out of pocket. Which would you prescribe?
  4. Imagine an adult patient newly diagnosed with a long-term condition you treat, who needs a daily medicine. Your preferred choice is a brand-name medicine with better trial results and fewer side effects. An older generic medicine also works, though somewhat less well, and costs the patient $5 a month. Under this patient’s insurance plan, the brand-name medicine would cost the patient $75 a month out of pocket. Which would you prescribe?
  5. Imagine an adult patient newly diagnosed with a long-term condition you treat, who needs a daily medicine. Your preferred choice is a brand-name medicine with better trial results and fewer side effects. An older generic medicine also works, though somewhat less well, and costs the patient $5 a month. Under this patient’s insurance plan, the brand-name medicine would cost the patient $150 a month out of pocket. Which would you prescribe?
  6. When a patient tells you they cannot afford the out-of-pocket cost of a brand-name medicine you prescribed, which one of these do you most often do?

What was not asked, and why

No medicine, condition, company or specialty was named, and specialty itself was not asked. The scenario did not offer a copay card or patient assistance, did not say how much less well the generic works, and did not describe the patient's income or plan. Ask Brox added one check that each clone is authorized to prescribe, which all 70 passed.

What changed from the obvious question

The obvious question asks doctors whether they consider cost. We gave the same 70 prescribers one patient three times, with a preferred brand-name medicine costing the patient $25, $75 and then $150 a month against a $5 generic, and asked which they would prescribe. Comparing each clone's own three answers shows where cost overrides clinical preference, not only whether prescribers say it matters.

Fielded through Ask Brox on 17 November 2026.

Ask this of your own customers: humans@brox.ai

Related insights

All in this topic